Group One Trading
TSHA icon

Group One Trading’s Taysha Gene Therapies TSHA Stock Holding History

Group One Trading’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.5K Sell
5,800
-35,600
-86% -$211K ﹤0.01% 5548
2026
Q1 		$185K Sell
41,400
-43,200
-51% -$201K ﹤0.01% 4176
2025
Q4 		$465K Buy
84,600
+49,200
+139% +$239K ﹤0.01% 3600
2025
Q3 		$116K Sell
35,400
-48,400
-58% -$137K ﹤0.01% 5206
2025
Q2 		$194K Buy
83,800
+52,300
+166% +$114K ﹤0.01% 4379
2025
Q1 		$43.8K Sell
31,500
-3,300
-9% -$5.52K ﹤0.01% 5263
2024
Q4 		$60.2K Buy
34,800
+33,600
+2,800% +$69.7K ﹤0.01% 4916
2024
Q3 		$2.41K Sell
1,200
-9,500
-89% -$20.8K ﹤0.01% 6101
2024
Q2 		$24K Sell
10,700
-28,300
-73% -$82.4K ﹤0.01% 5091
2024
Q1 		$112K Buy
39,000
+37,100
+1,953% +$77.3K ﹤0.01% 4063
2023
Q4 		$3.36K Sell
1,900
-26,100
-93% -$52K ﹤0.01% 6660
2023
Q3 		$88.5K Buy
28,000
+26,700
+2,054% +$49.9K ﹤0.01% 4565
2023
Q2 		$859 Buy
1,300
+700
+117% +$507 ﹤0.01% 7286
2023
Q1 		$479 Sell
600
-6,800
-92% -$8.78K ﹤0.01% 6910
2022
Q4 		$16.7K Buy
+7,400
New +$15K ﹤0.01% 5714

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Group One Trading's TSHA Position: Q2 2026 in Review

Group One Trading opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 1,939 shares worth $13.2K. The stake represents ﹤0.01% of the portfolio and ranks #6243 among its holdings. This is a return to the name: Group One Trading previously reported a position in TSHA as recently as Q4 2025.

Group One Trading first reported a position in TSHA in Q4 2022 and has held it in 7 quarters since. The position peaked at $243K in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Group One Trading held 1,939 shares of Taysha Gene Therapies worth $13.2K as of Q2 2026.
  • Taysha Gene Therapies was a new Group One Trading position in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6243 holding.
  • Group One Trading first reported a position in Taysha Gene Therapies in Q4 2022 and has held it in 7 quarters since.
  • Group One Trading's Taysha Gene Therapies position peaked at $243K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.